Lycia Therapeutics filed for a U.S. initial public offering after a surge in market activity. The company was founded by Nobel Prize winner Carolyn Bertozzi and is advancing a protein-degradation pipeline aimed at allergic conditions and Graves’ disease. The filing positions Lycia to fund clinical and platform development as it prepares for a potential public listing, with market narratives focusing on protein degradation modality differentiation. The IPO process also reflects continued capital demand for late-preclinical-to-clinical degrader assets. Separately within the same reporting bundle, other company-specific capital market movements and trial updates were highlighted, but Lycia’s IPO filing was the primary deal catalyst. Investors will likely seek clarity on lead program timelines, target validation rationale, and how Lycia’s approach compares with existing degradation toolsets in efficacy, tolerability, and manufacturing.